Letzte Aktualisierung: 05.04.2023
Urothelkarzinom der Blase
MoniTURB Trial
Studieninformationen
Xpert Bladder Cancer Monitor
to Predict Need for 2nd TURB
Ziele
Primäres Prüfziel
The primary objective of this prospective, multi-centre study is to determine if Xpert Monitor can predict the need for a second TURB better than the clinical risk assessment by predicting the presence of a residual tumor after a patient has undergone an initial resection to remove tumour (first TURB).
Sekundäre Prüfziele für die Behandlungsarme:
In a secondary objective, Xpert Monitor performance shall be established relative to cystoscopy in patients with non-muscle invasive bladder cancer (NMIBC) who, based on their clinical risk assessment, were not selected for second TURB but received a monitor cystoscopy 3-6 months after the first TURB.
Design
Phase
Zentren
Datenerhebung
Interventionsgruppen
Verblindung
Erkrankung
Diagnose
Diagnosenbeschreibung
Mutation
Stadium
Patienten
Alter
Einschlusskriterien
Ausschlusskriterien
Therapie
Intervention
Substanz
Sonstiges
Prüfplancode | MoniTURB Trial |
---|---|
EudraCT | - |
Clinicaltrials.gov | - |
---|---|
ISRCTN | - |
DRKS | - |
Zuständige Gesamtstudie
—
Leiter der klinischen Prüfung (LKP)—
Studiengruppen/-zentrale
Kontakt Klinische Studien
CIO Aachen: Uniklinik RWTH Aachen, +49 (0) 241 80-85490
CIO Bonn: Uniklinik Bonn, +49 (0) 228 287-16036
CIO Köln: Uniklinik Köln, +49 (0) 221 478-0
CIO Düsseldorf: Uniklinik Düsseldorf, +49 (0) 211 81-04150 (Mo-Do)